

Wolfgang P Fendler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9804016/publications.pdf>

Version: 2024-02-01

187
papers

9,543
citations

47006

47
h-index

43889

91
g-index

199
all docs

199
docs citations

199
times ranked

6702
citing authors

#	ARTICLE	IF	CITATIONS
1	German Multicenter Study Investigating ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 85-90.	5.0	646
2	⁶⁸ Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1014-1024.	6.4	589
3	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	7.1	493
4	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed mTNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	5.0	372
5	¹⁸ F-fluciclovine PET-CT and ⁶⁸ Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , The, 2019, 20, 1286-1294.	10.7	338
6	EANM procedure guidelines for radionuclide therapy with ¹⁷⁷ Lu-labelled PSMA-ligands (¹⁷⁷ Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	6.4	265
7	⁶⁸ Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. <i>European Urology</i> , 2016, 70, 553-557.	1.9	248
8	Dosimetry for ¹⁷⁷ Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 42-51.	6.4	244
9	⁶⁸ Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. <i>Journal of Nuclear Medicine</i> , 2018, 59, 230-237.	5.0	226
10	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	7.0	190
11	⁶⁸ Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1720-1725.	5.0	179
12	Preliminary experience with dosimetry, response and patient reported outcome after ¹⁷⁷ Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 3581-3590.	1.8	172
13	⁶⁸ Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. <i>Cancer Imaging</i> , 2016, 16, 14.	2.8	171
14	Metaanalysis of ⁶⁸ Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. <i>Journal of Nuclear Medicine</i> , 2019, 60, 786-793.	5.0	169
15	PSMA Ligands for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1545-1552.	5.0	165
16	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 67S-76S.	5.0	163
17	¹⁷⁷ Lu-PSMA Radioligand Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1196-1200.	5.0	159
18	The Impact of Somatostatin Receptor-Targeted PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 756-761.	5.0	158

#	ARTICLE	IF	CITATIONS
19	Radiation Dosimetry for ¹⁷⁷ Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2017, 58, 445-450.	5.0	144
20	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	7.1	138
21	Nomograms to predict outcomes after ¹⁷⁷ Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	10.7	120
22	Head-to-head intra-individual comparison of biodistribution and tumor uptake of ⁶⁸ Ga-FAPI and ¹⁸ F-FDG PET/CT in cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4377-4385.	6.4	114
23	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 434-441.	5.0	113
24	⁶⁸ Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	5.0	111
25	CD103 is a hallmark of tumor-infiltrating regulatory T cells. <i>International Journal of Cancer</i> , 2011, 129, 2417-2426.	5.1	104
26	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1153-1160.	5.0	94
27	Randomized prospective phase III trial of ⁶⁸ Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. <i>BMC Cancer</i> , 2019, 19, 18.	2.6	86
28	Potential Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1714-1721.	5.0	81
29	Validation of Several SUV-Based Parameters Derived from ¹⁸ F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1202-1208.	5.0	78
30	Predictive Value of ^{99m} Tc-MAA SPECT for ⁹⁰ Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1654-1660.	5.0	74
31	Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 812-821.	2.1	74
32	Impact of ⁶⁸ Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1793-1799.	5.0	74
33	PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷ Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1200-1210.	6.4	72
34	Comparison of ⁶⁸ Ga-PSMA-11 and ¹⁸ F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 789-794.	5.0	68
35	The diagnostic value of ¹⁸ F-FDG PET and MRI in paediatric histiocytosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 356-363.	6.4	65
36	Salvage PRRT with ¹⁷⁷ Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. <i>BMC Cancer</i> , 2019, 19, 788.	2.6	64

#	ARTICLE	IF	CITATIONS
37	Initial clinical experience with ⁹⁰ Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262468.	5.0	64
38	Nuclear medicine and multimodality imaging of pediatric neuroblastoma. <i>Pediatric Radiology</i> , 2013, 43, 418-427.	2.0	62
39	Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 227-233.	5.0	61
40	Pitfalls and Common Findings in ⁶⁸ Ga-FAPI PET: A Pictorial Analysis. <i>Journal of Nuclear Medicine</i> , 2022, 63, 890-896.	5.0	61
41	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. <i>EJNMMI Research</i> , 2018, 8, 96.	2.5	58
42	⁶⁸ Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸ Ga-FAPI PET Prospective Observational Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 89-95.	5.0	58
43	Serial ¹⁸ F-FET PET Imaging of Primarily ¹⁸ F-FET-Negative Glioma: Does It Make Sense?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1177-1182.	5.0	56
44	The diagnostic value of [18F]FDG PET for the detection of chronic osteomyelitis and implant-associated infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 749-761.	6.4	56
45	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. <i>Radiation Oncology</i> , 2018, 13, 37.	2.7	54
46	Diagnostic value of combined 18F-FDG PET/MRI for staging and restaging in paediatric oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1745-1755.	6.4	50
47	Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 517-523.	5.0	48
48	Safety and Efficacy of ⁹⁰ Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. <i>Clinical Cancer Research</i> , 2022, 28, 4346-4353.	7.0	45
49	Impact of ⁶⁸ Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 963-970.	5.0	44
50	PSMA ligands in prostate cancer – Probe optimization and theranostic applications. <i>Methods</i> , 2017, 130, 42-50.	3.8	43
51	Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. <i>European Radiology</i> , 2021, 31, 8714-8724.	4.5	43
52	Tumor Sink Effect in ⁶⁸ Ga-PSMA-11 PET: Myth or Reality?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 226-232.	5.0	42
53	Impact of ⁶⁸ Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum. <i>Annals of Surgical Oncology</i> , 2015, 22, 164-171.	1.5	41
54	Salvage lymph node dissection after ⁶⁸ Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients. <i>Oncotarget</i> , 2017, 8, 84180-84192.	1.8	41

#	ARTICLE	IF	CITATIONS
55	Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference. <i>Molecular Imaging and Biology</i> , 2020, 22, 788-796.	2.6	39
56	Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	1.9	39
57	⁶⁸ Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1235-1241.	5.0	39
58	Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1177-1188.	3.1	38
59	Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. <i>BMC Cancer</i> , 2020, 20, 326.	2.6	38
60	Prostate-specific Membrane Antigen PET in Prostate Cancer. <i>Radiology</i> , 2021, 299, 248-260.	7.3	38
61	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4271-4281.	6.4	38
62	In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CT. <i>Acta Biomaterialia</i> , 2020, 109, 244-253.	8.3	37
63	Prospective phase 2 trial of PSMA-targeted molecular Radiotherapy with ¹⁷⁷ Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1440-1446.	5.0	37
64	Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. <i>Journal of Nuclear Medicine</i> , 2016, 57, 2016-2021.	5.0	35
65	Establishing ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1786-1792.	5.0	35
66	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. <i>Prostate</i> , 2018, 78, 775-789.	2.3	35
67	Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. <i>Radiation Oncology</i> , 2017, 12, 176.	2.7	34
68	⁶⁸ Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. <i>Journal of Urology</i> , 2019, 202, 1174-1181.	0.4	33
69	Intraoperative ⁶⁸ Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1500-1506.	5.0	32
70	PET Response Criteria in Solid Tumors Predicts Progression-Free Survival and Time to Local or Distant Progression After Chemotherapy with Regional Hyperthermia for Soft-Tissue Sarcoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 530-537.	5.0	31
71	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. <i>European Urology Focus</i> , 2021, 7, 238-240.	3.1	31
72	High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1701-1710.	6.4	30

#	ARTICLE	IF	CITATIONS
73	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	6.4	30
74	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. <i>European Urology Oncology</i> , 2019, 2, 152-162.	5.4	29
75	¹⁸ F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis. <i>PLoS ONE</i> , 2020, 15, e0227906.	2.5	29
76	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263072.	5.0	28
77	⁶⁸ Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 307-311.	5.0	27
78	Targeted Prostate Biopsy Using ⁶⁸ Gallium PSMA-PET/CT for Image Guidance. <i>Urology Case Reports</i> , 2017, 14, 11-14.	0.3	25
79	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. <i>American Journal of Roentgenology</i> , 2018, 211, 286-294.	2.2	25
80	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7431.	4.1	25
81	Most of the Intended Management Changes After ⁶⁸ Ga-DOTATATE PET/CT Are Implemented. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1793-1796.	5.0	24
82	Imaging Inflammation with Positron Emission Tomography. <i>Biomedicines</i> , 2021, 9, 212.	3.2	24
83	Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence. <i>European Radiology</i> , 2015, 25, 2214-2221.	4.5	23
84	Prospective evaluation of whole-body MRI and ¹⁸ F-FDG PET/MRI in N and M staging of primary breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2816-2825.	6.4	23
85	Just another "Clever Hans"? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3141-3150.	6.4	23
86	Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. <i>European Radiology</i> , 2015, 25, 2693-2700.	4.5	22
87	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 355-360.	5.0	22
88	Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.256263.	5.0	22
89	Systematic Evaluation of Tumoral ^{99m} Tc-MAA Uptake Using SPECT and SPECT/CT in 502 Patients Before ⁹⁰ Y Radioembolization. <i>Journal of Nuclear Medicine</i> , 2015, 56, 333-338.	5.0	21
90	Detection Threshold and Reproducibility of ⁶⁸ Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1392-1397.	5.0	21

#	ARTICLE	IF	CITATIONS
91	Improving ⁶⁸ Ga-PSMA PET/MRI of the Prostate with Unrenormalized Absolute Scatter Correction. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1642-1648.	5.0	21
92	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 88-91.	5.0	21
93	Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. <i>European Radiology</i> , 2017, 27, 113-119.	4.5	20
94	[¹⁸ F]FDG PET accurately differentiates infected and non-infected non-unions after fracture fixation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 432-440.	6.4	20
95	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 76-80.	5.0	20
96	Multiparametric ¹⁸ F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Cancers</i> , 2022, 14, 1727.	3.7	20
97	¹⁸ F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1537-1542.	5.0	19
98	Can the Injected Dose Be Reduced in ⁶⁸ Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 189-193.	5.0	19
99	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1037-1042.	5.0	19
100	Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy. <i>PLoS ONE</i> , 2015, 10, e0132809.	2.5	18
101	Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 396-398.	5.0	18
102	Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 1015-1024.	0.8	18
103	Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 279-287.	3.1	17
104	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. <i>European Urology Oncology</i> , 2022, 5, 544-552.	5.4	16
105	Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2020, 41, 363-369.	1.1	16
106	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 675-678.	5.0	16
107	Evaluation of ¹⁸ F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision. <i>BMC Cancer</i> , 2021, 21, 62.	2.6	16
108	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	2.0	16

#	ARTICLE	IF	CITATIONS
109	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. <i>Oncotarget</i> , 2017, 8, 44131-44140.	1.8	16
110	¹⁸ F-PSMA-11 Versus ⁶⁸ Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. <i>European Urology</i> , 2022, 82, 501-509.	1.9	16
111	Reduced Periprocedural Analgesia After Replacement of Water for Injection with Glucose 5% Solution as the Infusion Medium for ⁹⁰ Y-Resin Microspheres. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1679-1684.	5.0	15
112	Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment. <i>Radiation Oncology</i> , 2016, 11, 37.	2.7	15
113	Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. <i>Journal of Nuclear Medicine</i> , 2021, 62, 146-148.	5.0	15
114	First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using ⁶⁸ Ga-PSMA-11. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3194-3195.	6.4	14
115	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. <i>BMC Cancer</i> , 2021, 21, 512.	2.6	14
116	Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷ Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). <i>Journal of Nuclear Medicine</i> , 2021, 62, 1447-1456.	5.0	14
117	⁶⁸ Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block? Early or Too Early to Draw Conclusions?. <i>European Urology</i> , 2016, 70, 938-940.	1.9	13
118	[¹⁸ F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors. <i>Oncology Research and Treatment</i> , 2021, 44, 400-407.	1.2	13
119	Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including ¹⁸ F-FDG PET/MRI, in Newly Diagnosed Breast Cancer: A Comparative Study Using Histopathology as the Reference Standard. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1677-1683.	5.0	13
120	More $\hat{\mu}$ Than $\hat{\sigma}^2$ for Prostate Cancer?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1709-1710.	5.0	12
121	Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer. <i>EJNMMI Physics</i> , 2021, 8, 14.	2.7	11
122	RESIST-PC phase 2 trial: ¹⁷⁷ Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5028-5028.	1.6	11
123	Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 191-194.	5.0	10
124	Evaluation of [⁶⁸ Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision. <i>EJNMMI Research</i> , 2021, 11, 21.	2.5	10
125	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 101-111.	0.6	10
126	A Role of PET/MR in Breast Cancer?. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 611-618.	4.6	10

#	ARTICLE	IF	CITATIONS
127	Safety of Radioembolization with ⁹⁰ Yttrium Resin Microspheres Depending on Coiling or No-Coiling of Aberrant/High-Risk Vessels. CardioVascular and Interventional Radiology, 2015, 38, 946-956.	2.0	9
128	Molecular Imaging for Primary Staging of Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 271-279.	4.6	9
129	Assessment of right ventricular sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy: An ¹²³ I-metaiodobenzylguanidine SPECT/CT study. Journal of Nuclear Cardiology, 2020, 27, 2402-2409.	2.1	8
130	Reduction of emission time for [⁶⁸ Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2023, 67, .	0.7	8
131	Diagnostic Performance of ¹²⁴ I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma. Journal of Nuclear Medicine, 2022, 63, 869-874.	5.0	8
132	Prospective head-to-head comparison of ¹⁸ F-fluciclovine and ⁶⁸ Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.. Journal of Clinical Oncology, 2019, 37, 15-15.	1.6	8
133	Reply: Comparison of ⁶⁸ Ga-PSMA-11 and ¹⁸ F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way. Journal of Nuclear Medicine, 2018, 59, 861-861.	5.0	7
134	Effect of stroke thrombolysis predicted by distal vessel occlusion detection. Neurology, 2018, 90, e1742-e1750.	1.1	7
135	Outcome After ⁶⁸ Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers, 2020, 12, 3395.	3.7	7
136	Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [¹⁸ F]FDG PET/CT and [¹⁸ F]FDG PET/MRI. Nuclear Medicine and Molecular Imaging, 2020, 54, 183-191.	1.0	7
137	PSMA-positive nodal recurrence in prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 637-646.	2.0	7
138	Virus-associated activation of innate immunity induces rapid disruption of Peyer's patches in mice. Blood, 2013, 122, 2591-2599.	1.4	6
139	PET imaging in prostate cancer, future trends: PSMA ligands. Clinical and Translational Imaging, 2016, 4, 467-472.	2.1	6
140	Repeatability of ⁶⁸ Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume. Journal of Nuclear Medicine, 2021, , jnumed.121.262528.	5.0	6
141	Accuracy of ⁶⁸ Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.. Journal of Clinical Oncology, 2018, 36, 5001-5001.	1.6	6
142	Correlation of Perfusion MRI and ¹⁸ F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation. PLoS ONE, 2015, 10, e0115543.	2.5	6
143	Effects of Anti-Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine. Arthritis and Rheumatology, 2022, 74, 1497-1505.	5.6	6
144	NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)-Directed Theranostics. Journal of Nuclear Medicine, 2017, 58, 934-935.	5.0	5

#	ARTICLE	IF	CITATIONS
145	Neoadjuvant chemoradiation for esophageal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 435-443.	2.0	5
146	A New Type of Prostate Cancer Imaging: Will 64CuCl ₂ PET/CT Flourish or Vanish?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 442-443.	5.0	5
147	Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. , 2021, 9, e002262.		5
148	Nuclear Medicine beyond VISION. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.262441.	5.0	5
149	A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 816-823.	4.6	5
150	Temporal factors in violence related injuries – An 11-year trend analysis of violence-related injuries from a Swiss Emergency Department. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 830-833.	1.9	4
151	What is the best PET target for early biochemical recurrence of prostate cancer? – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e609-e610.	10.7	4
152	Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension. <i>BMC Endocrine Disorders</i> , 2021, 21, 161.	2.2	4
153	Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging – utilization of a short-pass filter to reduce technical pitfalls. <i>Translational Andrology and Urology</i> , 2021, 10, 3972-3985.	1.4	4
154	Radiation Protection and Occupational Exposure on ⁶⁸ Ga-PSMA-11 – Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1349-1356.	5.0	4
155	Effectiveness of Reduced Radioiodine Activity for Thyroid Remnant Ablation after Total Thyroidectomy in Patients with Low to Intermediate Risk Differentiated Thyroid Carcinoma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2017, 56, 211-218.	0.7	3
156	Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 635-640.	1.8	3
157	Impact of PSMA PET/CT on SRT planning: Preliminary results from the randomized phase III trial NCT03582774. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-30.	1.6	3
158	Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS136-TPS136.	1.6	3
159	Imaging inflammation after myocardial infarction: implications for prognosis and therapeutic guidance. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 35-50.	0.7	3
160	Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. <i>European Urology Open Science</i> , 2020, 19, e1215-e1216.	0.4	2
161	2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2668-2669.	6.4	2
162	N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard. <i>EJNMMI Research</i> , 2021, 11, 68.	2.5	2

#	ARTICLE	IF	CITATIONS
163	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.7	2
164	Theranostics in oncology: What radiologists want to know. European Journal of Radiology, 2021, 142, 109875.	2.6	2
165	Safety and efficacy of ¹⁷⁷ Lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.. Journal of Clinical Oncology, 2017, 35, 155-155.	1.6	2
166	Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in ¹⁸ F-FDG PET/MRI. EJNMMI Physics, 2022, 9, 11.	2.7	2
167	Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium- ¹⁷⁷ Lu-prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) after radium- ²²³ (²²³Ra): Interim analysis of the RALU study.. Journal of Clinical Oncology, 2022, 40, 5040-5040.	1.6	2
168	Have we overcome choline PET/CT for early detection of prostate cancer recurrence?. Nuclear Medicine Communications, 2016, 37, 567-569.	1.1	1
169	Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245.. Journal of Clinical Oncology, 2021, 39, TPS172-TPS172.	1.6	1
170	PSMA-PET identifies PCWG3 target populations with high concordance however superior reproducibility when compared to conventional imaging. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	1
171	Randomized prospective phase 3 trial of ⁶⁸ Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. Journal of Clinical Oncology, 2019, 37, TPS5101-TPS5101.	1.6	1
172	Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice. Journal of Nuclear Medicine, 2022, 63, 1357-1363.	5.0	1
173	Positron emission tomography in pediatric and adult sarcoma. Clinical and Translational Imaging, 2015, 3, 83-93.	2.1	0
174	¹²³ I: Impact of the primary tumor metabolic volume (PT-MV) changes in the course of multimodality treatment on overall survival in patients with locally-advanced non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S109.	1.1	0
175	PD42-11 ⁶⁸ Ga-PSMA PET/CT PROVIDES ACCURATE STAGING OF LYMPH NODE REGIONS PRIOR TO LYMPH NODE DISSECTION IN PATIENTS WITH PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	0
176	A PET for All Seasons: ¹⁸ F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?. European Urology, 2017, 71, 934-935.	1.9	0
177	EP-1323: Role of ⁶⁸ Ga-PSMA PET/CT in radiotherapy for prostate cancer: A single centre experience. Radiotherapy and Oncology, 2017, 123, S709-S710.	0.6	0
178	⁶⁸ Ga-PSMA PET/CT Mapping of Prostate Cancer at Initial Staging: Potential Impact on Definitive Radiation Therapy Planning. International Journal of Radiation Oncology Biology Physics, 2018, 102, S162.	0.8	0
179	EP-1551: Outcome after PSMA PET based RT in patients with biochemical recurrence or persistence after surgery. Radiotherapy and Oncology, 2018, 127, S837.	0.6	0
180	¹⁸⁹ MO Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. Annals of Oncology, 2020, 31, S1076-S1077.	1.2	0

#	ARTICLE	IF	CITATIONS
181	We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 227-228.	3.1	0
182	REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.262271.	5.0	0
183	Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
184	Textural analysis of DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, .	0.7	0
185	Prospective head-to-head comparative phase 3 study between ¹⁸ F-fluciclovine and ⁶⁸ Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5014-5014.	1.6	0
186	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 1181-1181.	0.4	0
187	SAT0365â€¦EFFECTS OF ANTI-TNF-THERAPY ON OSTEOBLASTIC ACTIVITY IN ANKYLOSING SPONDYLITIS â€œ RESULTS FROM A PROSPECTIVE STUDY USING PET-MRI OF SIJ AND SPINE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1129.2-1130.	0.9	0